UNH

524.95

+1.56%↑

JNJ

166.07

+1.41%↑

ABBV

207.28

+0.93%↑

NVO

68.54

-1.18%↓

AZN

72.62

-1.61%↓

UNH

524.95

+1.56%↑

JNJ

166.07

+1.41%↑

ABBV

207.28

+0.93%↑

NVO

68.54

-1.18%↓

AZN

72.62

-1.61%↓

UNH

524.95

+1.56%↑

JNJ

166.07

+1.41%↑

ABBV

207.28

+0.93%↑

NVO

68.54

-1.18%↓

AZN

72.62

-1.61%↓

UNH

524.95

+1.56%↑

JNJ

166.07

+1.41%↑

ABBV

207.28

+0.93%↑

NVO

68.54

-1.18%↓

AZN

72.62

-1.61%↓

UNH

524.95

+1.56%↑

JNJ

166.07

+1.41%↑

ABBV

207.28

+0.93%↑

NVO

68.54

-1.18%↓

AZN

72.62

-1.61%↓

Search

Eli Lilly and Co.

Avatud

SektorTervishoid

813 -0.98

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

789.04

Max

821.04

Põhinäitajad

By Trading Economics

Sissetulek

3.4B

4.4B

Müük

2.1B

14B

P/E

Sektori keskmine

73.734

73.239

Aktsiakasum

5.32

Dividenditootlus

0.72

Kasumimarginaal

32.586

Töötajad

47,000

EBITDA

1.2B

6.1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+24.34% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.72%

3.06%

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-8B

777B

Eelmine avamishind

813.98

Eelmine sulgemishind

813

Uudiste sentiment

By Acuity

25%

75%

44 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. märts 2025, 15:54 UTC

Peamised uudised

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26. veebr 2025, 15:14 UTC

Peamised uudised

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26. veebr 2025, 14:30 UTC

Peamised uudised

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10. veebr 2025, 12:00 UTC

Peamised uudised

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7. veebr 2025, 10:30 UTC

Peamised uudised

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6. veebr 2025, 16:16 UTC

Peamised uudised
Tulu

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6. veebr 2025, 14:56 UTC

Tulu

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6. veebr 2025, 14:32 UTC

Market Talk
Tulu

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6. veebr 2025, 13:18 UTC

Peamised uudised
Tulu

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6. veebr 2025, 12:24 UTC

Tulu

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6. veebr 2025, 12:01 UTC

Tulu

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6. veebr 2025, 11:49 UTC

Tulu

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6. veebr 2025, 11:48 UTC

Tulu

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6. veebr 2025, 11:47 UTC

Tulu

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6. veebr 2025, 11:46 UTC

Tulu

Eli Lilly 4Q Gross Margin 82.2% >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly Sees FY Rev $58B-$61B >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Net $4.41B >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q EPS $4.88 >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Rev $13.53B >LLY

6. veebr 2025, 11:45 UTC

Tulu

Eli Lilly 4Q Adj EPS $5.32 >LLY

5. veebr 2025, 21:23 UTC

Peamised uudised

Eli Lilly's Results Already Disappointed the Street. More Details Come Thursday. -- Barrons.com

5. veebr 2025, 12:02 UTC

Tulu

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5. veebr 2025, 12:00 UTC

Peamised uudised

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

24.34% tõus

12 kuu keskmine prognoos

Keskmine 1,022.71 USD  24.34%

Kõrge 1,146 USD

Madal 900 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

18

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

813.48 / 824.76Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

44 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.